|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/06/20 Orthofix Medical Inc. 10-Q 6/30/20 81:10M ActiveDisclosure/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 969K
2: EX-10.2 Material Contract HTML 96K
3: EX-31.1 Certification -- §302 - SOA'02 HTML 31K
4: EX-31.2 Certification -- §302 - SOA'02 HTML 30K
5: EX-32.1 Certification -- §906 - SOA'02 HTML 27K
12: R1 Document and Entity Information HTML 77K
13: R2 Condensed Consolidated Balance Sheets HTML 108K
14: R3 Condensed Consolidated Balance Sheets HTML 35K
(Parenthetical)
15: R4 Condensed Consolidated Statements of Income and HTML 114K
Comprehensive Income (Loss)
16: R5 Condensed Consolidated Statements of Changes in HTML 75K
Shareholders' Equity
17: R6 Condensed Consolidated Statements of Cash Flows HTML 123K
18: R7 Business, basis of presentation, COVID-19 update, HTML 41K
and CARES Act
19: R8 Recently adopted accounting standards and recently HTML 46K
issued accounting pronouncements
20: R9 Acquisitions HTML 93K
21: R10 Inventories HTML 46K
22: R11 Leases HTML 102K
23: R12 Other current liabilities HTML 27K
24: R13 Long-term debt HTML 27K
25: R14 Fair value measurements and investments HTML 155K
26: R15 Contingencies HTML 29K
27: R16 Accumulated other comprehensive loss HTML 46K
28: R17 Revenue recognition and accounts receivable HTML 260K
29: R18 Business segment information HTML 183K
30: R19 Acquisition-Related Amortization and Remeasurement HTML 55K
31: R20 Share-based compensation HTML 108K
32: R21 Income taxes HTML 31K
33: R22 Earnings per share ("Eps") HTML 69K
34: R23 Subsequent Events HTML 27K
35: R24 Recently adopted accounting standards and recently HTML 38K
issued accounting pronouncements (Policies)
36: R25 Acquisitions (Tables) HTML 92K
37: R26 Inventories (Tables) HTML 47K
38: R27 Leases (Tables) HTML 102K
39: R28 Fair value measurements and investments (Tables) HTML 159K
40: R29 Accumulated other comprehensive loss (Tables) HTML 45K
41: R30 Revenue recognition and accounts receivable HTML 259K
(Tables)
42: R31 Business segment information (Tables) HTML 180K
43: R32 Acquisition-Related Amortization and Remeasurement HTML 54K
(Tables)
44: R33 Share-based compensation (Tables) HTML 108K
45: R34 Earnings per share ("Eps") (Tables) HTML 67K
46: R35 Business, basis of presentation, COVID-19 update, HTML 51K
and CARES Act - Additional information (Detail)
47: R36 Recently Adopted Accounting Standards and Recently HTML 54K
Issued Accounting Pronouncements - Additional
Information (Detail)
48: R37 Acquisitions - Additional Information (Detail) HTML 57K
49: R38 Acquisitions - Summary of Fair Values of Assets HTML 68K
Acquired and Liabilities Assumed (Detail)
50: R39 Inventories - Schedule of Inventories (Detail) HTML 35K
51: R40 Leases - Summary of Lease Portfolio (Detail) HTML 52K
52: R41 Leases - Summary of Supplemental Cash Flow HTML 38K
Information Related to Leases (Detail)
53: R42 Leases - Additional Information (Detail) HTML 37K
54: R43 Other Current Liabilities - Additional Information HTML 35K
(Detail)
55: R44 Long-Term Debt - Additional Information (Detail) HTML 44K
56: R45 Fair Value Measurements and Investments - Schedule HTML 43K
of Financial Assets and Liabilities Measured at
Fair Value on Recurring Basis (Detail)
57: R46 Fair Value Measurements and Investments - HTML 50K
Additional Information (Detail)
58: R47 Fair Value Measurements and Investments - Schedule HTML 33K
of Reconciliation For Contingent Consideration
Measured At Fair Value Using Significant
Unobservable Inputs (Level 3) (Detail)
59: R48 Fair Value Measurements and Investments - Schedule HTML 43K
of Valuation Methodology and Unobservable Inputs
for Level 3 Assets and Liabilities Measured at
Fair Value (Detail)
60: R49 Fair Value Measurements and Investments - Schedule HTML 38K
of Reconciliation of Debt Security and Warrant
(Detail)
61: R50 Contingencies - Additional Information (Detail) HTML 32K
62: R51 Accumulated Other Comprehensive Loss - Components HTML 36K
of Changes in Accumulated Other Comprehensive Loss
(Detail)
63: R52 Revenue Recognition and Accounts Receivable - HTML 45K
Schedule of Net Sales by Major Product Category by
Reporting Segment (Detail)
64: R53 Revenue Recognition and Accounts Receivable - HTML 33K
Schedule of Components of Net Sales (Detail)
65: R54 Revenue Recognition and Accounts Receivable - HTML 48K
Additional Information (Detail)
66: R55 Revenue Recognition and Accounts Receivable - HTML 97K
Schedule of Net Impact of Adoption to Balance
Sheet (Detail)
67: R56 Revenue Recognition and Accounts Receivable - HTML 34K
Schedule of Allowance for Expected Credit Losses
(Detail)
68: R57 Business Segment Information - Additional HTML 26K
Information (Detail)
69: R58 Business Segment Information - Summary of EBIDTA HTML 44K
by Reporting Segment (Detail)
70: R59 Business Segment Information - Summary of Net HTML 44K
Sales by Geographic Destination for Each Reporting
Segment (Detail)
71: R60 Acquisition-Related Amortization and Remeasurement HTML 31K
- Components of Acquisition-Related Amortization
and Remeasurement (Detail)
72: R61 Share-based Compensation - Schedule of Components HTML 47K
of Share-Based Compensation Expense (Detail)
73: R62 Share-based Compensation - Additional Information HTML 26K
(Detail)
74: R63 Income Taxes - Additional Information (Detail) HTML 42K
75: R64 Earnings Per Share ("EPS") - Schedule of HTML 39K
Reconciliation of Weighted Average Shares Used in
Diluted EPS (Detail)
76: R65 Earnings Per Share ("EPS") - Additional HTML 30K
Information (Detail)
77: R66 Subsequent Events - Additional Information HTML 43K
(Detail)
79: XML IDEA XML File -- Filing Summary XML 151K
11: XML XBRL Instance -- ofix-10q_20200630_htm XML 2.75M
78: EXCEL IDEA Workbook of Financial Reports XLSX 90K
7: EX-101.CAL XBRL Calculations -- ofix-20200630_cal XML 176K
8: EX-101.DEF XBRL Definitions -- ofix-20200630_def XML 561K
9: EX-101.LAB XBRL Labels -- ofix-20200630_lab XML 1.14M
10: EX-101.PRE XBRL Presentations -- ofix-20200630_pre XML 921K
6: EX-101.SCH XBRL Schema -- ofix-20200630 XSD 187K
80: JSON XBRL Instance as JSON Data -- MetaLinks 367± 562K
81: ZIP XBRL Zipped Folder -- 0001564590-20-037284-xbrl Zip 212K
Exhibit 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Orthofix Medical Inc. (“Orthofix”) on Form 10-Q for the quarterly period ended June 30, 2020, (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, Jon Serbousek, Chief Executive Officer and President of Orthofix, and Doug Rice, Chief Financial Officer, each certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to his knowledge:
|
1. |
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
2. |
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Orthofix. |
|
Dated: August 6, 2020 |
/s/ JON SERBOUSEK |
|
|
|
Name: |
|
|
|
Title: |
President and Chief Executive Officer |
|
|
|
|
|
|
|
|
|
Dated: August 6, 2020 |
/s/ DOUG RICE |
|
|
|
Name: |
|
|
|
Title: |
Chief Financial Officer |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 8/6/20 | 8-K | ||
| For Period end: | 6/30/20 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/26/21 Orthofix Medical Inc. 10-K 12/31/20 124:22M ActiveDisclosure/FA 11/05/20 Orthofix Medical Inc. 10-Q 9/30/20 82:10M ActiveDisclosure/FA 9/14/20 Orthofix Medical Inc. S-8 9/14/20 5:388K ActiveDisclosure/FA |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 6/09/20 Orthofix Medical Inc. 8-K:5,7,9 6/08/20 12:212K ActiveDisclosure/FA |